Bausch Health Companies Inc. to Post Q2 2024 Earnings of $1.18 Per Share, Zacks Research Forecasts (TSE:BHC)

Bausch Health Companies Inc. (TSE:BHC) – Zacks Research increased their Q2 2024 EPS estimates for Bausch Health Companies in a research note issued on Tuesday, June 25th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.18 for the quarter, up from their prior estimate of $1.17. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2024 earnings at $1.41 EPS, FY2024 earnings at $4.90 EPS and Q4 2025 earnings at $1.78 EPS.

Bausch Health Companies (TSE:BHC) last posted its earnings results on Thursday, May 2nd. The company reported C$0.80 earnings per share for the quarter, missing analysts’ consensus estimates of C$1.02 by C($0.22). The business had revenue of C$2.90 billion during the quarter, compared to analysts’ expectations of C$2.98 billion. Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 686.52%.

Bausch Health Companies Stock Up 1.3 %

Shares of BHC opened at C$9.54 on Friday. The company has a market cap of C$3.50 billion, a PE ratio of -5.64, a P/E/G ratio of 0.21 and a beta of 0.90. The business has a fifty day moving average of C$9.57 and a 200 day moving average of C$10.96. Bausch Health Companies has a 52-week low of C$8.32 and a 52-week high of C$15.43. The company has a quick ratio of 0.58, a current ratio of 1.23 and a debt-to-equity ratio of 7,583.76.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.